COVID-19 information and response
  • HOME
  • WHO WE ARE
    • About Us
      • CHS is a local, not-for-profit organisation. We understand the local context, make use of local expertise and strategic partnerships to ensure we implement evidence-informed solutions and interventions to existing and emerging public health concerns.
      • Learn more >>
    • More About Us
      • Our Approach
      • Our Strategic Goals
      • Our Solutions
    • Leadership & Partners
      • Board and Leadership
      • Partners
  • WHAT WE DO
    • Our Solutions
      • CHS continues to grow as the preferred partner for health solutions by consistently focusing on the delivery of quality services and continuous improvement in a transparent and accountable manner.
      • Learn More >>
    • Current Programmes
      • Tamatisha TB
      • TIFA Project
      • Shinda Tena
    • Our Impact
      • Our Impact
      • Focus Areas
      • Tuberculosis in Kenya
    • Past Programmes
      • TB ARC II
      • TB ARC
      • Diagnostics Project
      • Tibulims Project
      • Ezesha_99DOTS Project
      • Tegemeza Plus
      • Shinda
      • Tegemeza
      • Naishi
      • Fikia
      • Afya Info
      • ALHIV Adherence Initiative
  • MEDIA CENTRE
    • News
      • CHS continues to grow as the preferred partner for health solutions by consistently focusing on the delivery of quality services and continuous improvement in a transparent and accountable manner.
      • View >>
    • Blog
      • CHS continues to grow as the preferred partner for health solutions by consistently focusing on the delivery of quality services and continuous improvement in a transparent and accountable manner.
      • View >>
    • Personal Stories
      • CHS continues to grow as the preferred partner for health solutions by consistently focusing on the delivery of quality services and continuous improvement in a transparent and accountable manner.
      • View >>
    • More
      • Video Gallery
  • RESOURCES
    • Papers
      • CHS continues to grow as the preferred partner for health solutions by consistently focusing on the delivery of quality services and continuous improvement in a transparent and accountable manner.
      • View >>
    • Job Aids and Tools
      • CHS continues to grow as the preferred partner for health solutions by consistently focusing on the delivery of quality services and continuous improvement in a transparent and accountable manner.
      • View >>
    • Best Practices
      • CHS continues to grow as the preferred partner for health solutions by consistently focusing on the delivery of quality services and continuous improvement in a transparent and accountable manner.
      • View >>
    • More
      • Annual Reports
      • Newsletters
      • Publications
  • GET INVOLVED
    • Careers
      • CHS continues to grow as the preferred partner for health solutions by consistently focusing on the delivery of quality services and continuous improvement in a transparent and accountable manner.
      • View Careers >>
    • Partner With Us
      • CHS continues to grow as the preferred partner for health solutions by consistently focusing on the delivery of quality services and continuous improvement in a transparent and accountable manner.
      • Learn more >>
    • Subscribe
      • CHS continues to grow as the preferred partner for health solutions by consistently focusing on the delivery of quality services and continuous improvement in a transparent and accountable manner.
      • Subscribe >>
  • CONTACT US
+321 123 4567
info@test.com
My Account

Smartphone- Enabled Video Directly Observed Therapy to Improve Viral Suppression among Unsuppressed Children and Adolescents in Kenya

Posted on August 3, 2023

Paul Wekesa1, Margaret Ndisha2 , Boniface Makone2, Kevin Kamenwa1, Kevin Owuor1 Immaculate Mutisya2

  1. Centre for Health Solutions – Kenya
  2. Division of Global HIV&TB (DGHT), Center for Global Health, U.S. Centers for Disease Control and Prevention (CDC), Kisumu, Kenya

Background

Video directly observed therapy (vDOT) has been used as an acceptable, cost-effective, client-centered intervention for tuberculosis management. vDOT targeting children and adolescents not achieving viral suppression (VS) [<1000 copies/ml] was piloted in 128 sites in Kenya. We evaluated utilization and re-suppression rates of clients enrolled in vDOT.

Methods

A retrospective review of data from 223 (out of 470) virally unsuppressed clients aged between 0-19 years on antiretroviral therapy (ART) using the NimeCONFIRM vDOT application for at least 12 weeks between February 2021 and October 2022 at 73 facilities were conducted. Clients stopped using the application upon achieving VS.  VS was assessed after at least 12 weeks of follow-up through self-care (user) or Healthcare worker (HCW)-assisted recording and upload of vDOT. Using a multivariable Fine‐Gray sub distribution hazard (SH) model we assessed demographic and clinical determinants of VS presenting adjusted sub distribution hazard ratios (aSHR) and 95% confidence interval (CI). Participants were censored on loss to follow-up, death, and transfers .

Results

Most users were aged 10-14 years (84 [37.7%])  and 15-19 years (79 [35.4%]) . Only 19 (8.5%) were on selfcare vDOT.  Median time on follow up was 19.36 weeks (interquartile range [IQR]: 16.50 – 23.07), median number of videos uploaded were 126 (IQR: 96 -197), and with 75% (IQR: 60% – 85%) vDOT adherence.

About half, 108 (48.4%),%) were active, 39 (17.5%) had achieved VS, and 76 (34.1 %) discontinued. Cumulative incidence of VS was 22.1%. Results show higher incidence of VS among children aged 5-9 years compared to 0-4 years, aSHR = 3.12 (95% CI: 1.03 – 9.39) and those on self-care compared to healthcare worker led option, aSHR = 2.51 (95% CI: 1.95 – 3.24). Similarly, there was higher incidence of VS for those with guardians and siblings as caregivers compared to grandparents; aSHR = 1.28 (95% CI: 1.11- 1.48), and aSHR = 2. 83 (95% CI: 1.83 – 4.37), respectively.

Conclusion:

Achieving VS using vDOT was significantly associated with age, self-care option, and type of caregiver. Findings suggest vDOT as an additional tool to support unsuppressed children and adolescents to achieve more equitable health outcomes.

Table 1. Gray-Fine competing risks model for viral suppression during the follow up period while using the NIMECONFIRM application (At least 12 weeks)

Outcome: Viral Suppression while using app * Subdistribution Hazard Ratio ^   Adjusted Sub-distribution Hazard Ratio ^  
User Characteristics SHR (95% CI) P value aSHR (95% CI) P value
Sex
Girls Reference Reference
Boys 1.29 (0.83 – 2.00) 0.265 1.56  (0.78 – 3.11) 0.209
Age Category
0-4yrs Reference Reference
5-9yrs 3.40 (0.99 – 11.71) 0.052 3.12 (1.03 – 9.39) 0.043
10-14yrs 2.05 (0.50 – 8.49) 0.32 1.78  (0.58 – 5.41) 0.312
15-19yrs 1.46 (0.32 – 6.62) 0.625 1.06 (0.26 – 4.31) 0.937
Caregiver
Grandfather Reference Reference
Guardian 1.24 (1.00 – 1.54) 0.054 1.28 (1.11 – 1.48) 0.001
Parent 0.94 (0.53 – 1.68) 0.841 1.03 (0.60 – 1.77) 0.927
Relative 1.25 (0.72 – 2.17) 0.431 1.69 (0.67 – 4.23) 0.264
Siblings 1.96 (1.72 – 2.24) <0.001 2.83 (1.83 – 4.37) <0.001
Dosage Frequency
Twice Daily Reference Reference
Once Daily 1.68 (1.22 – 2.30) 0.001 1.42  (0.53 – 3.86) 0.488
Core regimen
ABC Based Reference Reference
AZT Based 2.08 (1.42 – 3.04) <0.001 1.62 (0.87 – 3.01) 0.128
TDF Based 1.88 (1.09 – 3.23) 0.022 1.83 (0.54 – 6.16) 0.329
Care Type
Healthcare Worker Led Reference Reference
Self-Care 2.051.33 – 3.15) 0.001 2.51 (1.95 – 3.24) <0.001

* Any discontinuation was a competing event

^ Project level clustering accounted for

Figure 1. Cumulative Incidence of Viral Suppression by Age Category after 12 weeks of using application

Figure .2. Cumulative Incidence of Viral Suppression by Caregiver type after 12 of weeks using application

Search

About CHS

CHS is a local, not-for-profit organisation. We understand the local context, make use of local expertise and strategic partnerships to ensure we implement evidence-informed solutions and interventions to existing and emerging public health concerns. Learn more >>

Recent Posts

  • Consultancy for Organizational Capacity Assessment of the Division Of National Tuberculosis and Other Lung Diseases July 10, 2025
  • VIPASHO Returns: Latest Updates on Our Impact and Progress July 2, 2025
  • Invitation to Bid Sale of Motor Vehicle June 30, 2025
  • Using survival analysis to identify risk factors for treatment interruption among new and retreatment tuberculosis patients in Kenya June 27, 2025
  • Time to HIV testing of sexual contacts identified by HIV-positive index clients in Siaya County, Kenya June 27, 2025

News & Features

News
Blog
Case Studies
Personal Stories
Newsletters
Annual Reports
Job Aids & Tools
Meeting Reports
Papers
Events

Quick Links

Our Programs
Focus Areas
HIV/AIDS in Kenya
Tuberculosis in Kenya
One
Our Impact
Our Finances

Get Involved

Careers
Partner
Subscribe

Facebook
Twitter
LinkedIn
YouTube

2023. Center for Health Solutions – Kenya(CHS)

Watermark Business Park | Spring Court | First Floor | Ndege Road, Karen